

TE-MPN- Thrombotic events in myeloproliferative neoplasms: JAK2V617F mutation as a predictive marker

Adel Gouri

IBN ZOHR Public Hospital, Algeria

Thrombotic complications are a common cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). The pathogenesis of thrombosis in MPN is multifactorial and complex. Recently, several studies suggest that JAK2V617F mutation plays an important role in the pathogenesis of thrombosis. This mutation is present in almost all the PV patients and in 50-60% of ET patients. This relationship suggests a direct influence of the JAK2 mutation on the hemostatic system. Current data indicate that JAK2V617F mutation positivity seem to be predictive biomarker of cardiovascular and thrombotic complications in patients with MPN. However, future research should focus on the pathophysiology of thrombosis in myeloproliferative disorders, particularly in terms of the relationship between dysregulated Janus kinase 2 and thrombotic risks.

Biography

Adel Gouri completed his Pharm.D. and Clinical Biochemistry Specialization in 2008 from Badji-Mokhtar University, School of Medicine, Annaba, Algeria. He is the director of Laboratory of Clinical Biochemistry at Ibn Zohr Public Hospital, Guelma, Algeria. He is also a visiting lecturer to the National Institute of Paramedical Sciences, Annaba, Algeria and the University of Guelma, Algeria. He has published several publications in the field and serving as a reviewer and editorial board member of more than 20 reputable/international journals.

pharmagor@gmail.com